Cofetuzumab pelidotin
Cofetuzumab Pelidotin[edit | edit source]
Cofetuzumab pelidotin is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It combines a monoclonal antibody with a potent cytotoxic agent, allowing for targeted delivery of the drug to cancer cells.
Mechanism of Action[edit | edit source]
Cofetuzumab pelidotin works by targeting specific antigens expressed on the surface of cancer cells. The monoclonal antibody component of the ADC binds to these antigens, facilitating the internalization of the entire complex into the cell. Once inside, the cytotoxic agent, pelidotin, is released, leading to cell death by disrupting critical cellular processes.
Development and Clinical Trials[edit | edit source]
The development of cofetuzumab pelidotin involves extensive preclinical and clinical trials to evaluate its safety and efficacy. Initial studies focus on determining the optimal dosage and assessing potential side effects. Subsequent phases involve larger patient populations to confirm its therapeutic benefits and compare it to existing treatment options.
Applications[edit | edit source]
Cofetuzumab pelidotin is primarily investigated for use in hematologic malignancies and certain solid tumors. Its ability to selectively target cancer cells while sparing normal tissues makes it a promising candidate for personalized medicine.
Side Effects[edit | edit source]
As with many cancer therapies, cofetuzumab pelidotin can cause a range of side effects. Common adverse effects include nausea, fatigue, and myelosuppression. More severe reactions may occur, necessitating careful monitoring during treatment.
Future Directions[edit | edit source]
Ongoing research aims to enhance the efficacy of cofetuzumab pelidotin by optimizing its antibody component and exploring combination therapies. Advances in biotechnology may lead to the development of next-generation ADCs with improved targeting capabilities and reduced toxicity.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
